ARTICLE | Clinical News

Votrient pazopanib: Phase I/II started

January 6, 2014 8:00 AM UTC

On Dec. 18, 2013, Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) said GlaxoSmithKline began an open-label Phase I/II trial of Merck's IV MK-3475 in combination with GSK's oral pazopanib in about 228 treatment-naïve patients with advanced RCC. The Phase I portion will evaluate escalating doses of pazopanib and MK-3475, followed by an expansion cohort to determine the maximum tolerated regimen and recommended Phase II dose. The Phase II portion will compare the combination vs. pazopanib and MK-3475 as single agents. The companies are partnered to evaluate a combination of MK-3475 with pazopanib and other undisclosed GSK compounds. ...